CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Insulin glargine (rDNA origin)

Last Updated: February 11, 2005
Result type: Reports
Project Number: SR0033-000
Product Line: Reimbursement Review

Generic Name: Insulin glargine (rDNA origin)

Brand Name: Lantus

Manufacturer: Aventis Pharma Inc.

Therapeutic Area: Diabetes mellitus, Type 1 & 2

Indications: Diabetes mellitus, Type 1 & 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 28, 2005

Recommendation Type: Do not list